Full Prescribing Info
Dosage/Direction for Use

Passive immunisation of infants against lower respiratory tract infections
Child: <2 yr 15 mg/kg mthly during the season of resp syncytial virus (RSV) risk. Subsequent doses should be given mthly until the end of the season. Undergone cardiac bypass surgery: 15 mg/kg as soon as stable post-op. Admin preferably in the anterolateral thigh; vol >1 mL should be given in divided doses.
Hypersensitivity to palivizumab or other humanised monoclonal antibodies.
Special Precautions
Patient w/ thrombocytopenia or other coagulation disorder, moderate to severe acute infection or febrile illness. Not intended for use in adult. Pregnancy and lactation.
Adverse Reactions
Fever, inj site reactions, nervousness, diarrhoea, vomiting, constipation, haemorrhage, rhinitis, cough, wheeze, pain, drowsiness, asthenia, hyperkinesia, leucopenia, rash, apnoea, convulsions, thrombocytopenia.
Potentially Fatal: Anaphylaxis and anaphylactic shock.
Lab Interference
May cause false-negative result w/ immunological-based RSV diagnostic test e.g. some antigen detection based assay.
Palivizumab is a recombinant humanised monoclonal antibody which targets the surface glycoprotein, responsible for recognition and entry into the cell on the resp syncytial virus (RSV).
Absorption: Well absorbed. Bioavailability: 70%.
Excretion: Elimination half-life: 24.5 days.
Intramuscular: Store between 2-8°C. Do not freeze.
ATC Classification
J06BB16 - palivizumab ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Disclaimer: This information is independently developed by CIMS based on palivizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in